Skip to main content
ALXO $1.06 +3.92%
ALXO logo
ALXO · Alx Oncology Holdings Inc
Track ALXO — free
$1.06 +0.04 (+3.92%) At close · Nov 20 Play latest call Q1 2026 earnings call transcript
Market Cap
$137.03M
Shares
129.27M
Volume · Nov 20 997.71K Avg daily vol (3M) 1.18M
All webcasts

Conference · 2026-11-17

Alx Oncology Holdings Inc (ALXO) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay Verified speakers
Nov 17, 2026 30:02 100 turns
Period
2026-11-17
Runtime
30:02
Sources
2 artifacts

Transcript & audio

Verified speakers 30:02 Audio
Speaker 2

Good afternoon, everyone.

Michael Yee Analyst — UBS

Thank you for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research here at UBS, and I'm very pleased to have members of the ALX Oncology team with us, including Jason Lettman, Chief Executive Officer and Chief Medical Officer. A couple of things I would love to start off. Jason, you just reported earnings, not because we were talking about revenue and EPS, but because we're talking about... That's right. I'm talking about the pipeline and the developments and how you're going there. And so there's two programs we want to talk about today. Obviously, EvorpaSep, which is at CD47 for breast cancer. I'm going to talk about that because there's a major phase two readout that will be coming next year and a multi-billion dollar indication. And also something that people are not as familiar with, which is ALX2004, which is an EGFR antibody drug conjugate, which has data soon. So maybe I could just start with something new, which is this data coming up. So I want you to maybe set the stage for EGFR antibody drug conjugates, something that people are not as familiar with. And I would argue that antibody drug conjugates are some of the hottest technologies in oncology right now. And so this could be really attractive, but people are still learning about EGFR. Yeah, sure. We can talk a little bit about that.

Speaker 2

Because data is coming very, very soon.

Very soon, in December. We just updated that as part of the earnings. And first of all, just thank you for having us. We've had a great day here. Great conference. You know, I think we're excited about both programs. Both are going to have really important inflection points. We were just talking, you know, our hope this time next year is we're on the doorstep of two registrational studies if we continue to execute. And I think are well on our way. So to your point on ALX 2004, we have data coming next month. This has been a long time coming for this program. I think as you've followed, you know, we designed, created, built this antibody drug conjugate in-house at ALX. We've been working on this program since 2021. We kept it under wraps for many years and then started in the clinic about 12, 13 months ago or so. So this data that's coming will be reporting from our phase one study. I think as we've discussed with you before, we really have been encouraged by what we've seen on enrollment. We've been encouraged by the way we've been able to escalate in terms of our dose. And as I think has been covered, EGFR has been a tough target for an ADC. It's expressed in healthy cells just like it is in tumor. The on-target toxicities have been a challenge, and the way that we designed ALX 2004 was really to address that. And we also spent a lot of time optimizing the potency.

Michael Yee Analyst — UBS

Specifically that if you go back and look at some of the prior EGFR antibody drug conjugates, I mean, let's be frank, EGFR has been a target that's been around for a long time with monoclonal antibodies. And that's great for binding EGFR and having anti-drug activity by dragging ADCC and other activities there. By using it as a target to find cancer cells and then bring a payload to it could be very powerful, hence the excitement of ADCs. But if you're going to hit EGFR in the skin, we're not only going to have a lot of rash, you're brain toxicity, you're going to have a lot of rash. Right. So you believe that you have found an epitope along the EGFR that is only expressed in cancer cells, not in the skin. Can you just describe that?

We think it's so, and you're right, it's been really challenging. We know big pharma has had monospecific ADCs against EGFR that have failed, and we really went to school on both the history of EGFR antibody development as well as those failures. And one of the decisions we made was choosing metuzumab. And metuzumab was developed by Big Pharma to uniquely bind EGFR.

Speaker 2

Where did this come from?

EMD Sirono. And they took this through the clinic and put a lot of time and money into this program. And what they found in the clinic was that, in fact, they were not having the same skin-related issues that the other EGFRs like Cetuximab saw. And so we thought that'd be the perfect epitope to use as an ADC. We thought that could have more preferential binding to tumor. We also know it internalizes at the same rate as Cetuxnav, so it's really the perfect vehicle to deliver a payload. Okay.

Michael Yee Analyst — UBS

So, in prior studies, the monoclonal antibody does not have the skin rash that the others have. Therefore, you feel pretty good about that. Now, we're going to drag an ADC and a payload to it, and we need to prove that with your construct. So, I think two things. One is, in a multiple ascending dose cohort, we want to have good safety and tolerability, meaning less rash. I'm Let you answer that question. How much rash is okay versus other antibodies? And then two is we like efficacy. Not having any rash is good, but if we're not shrinking tumors, that's no good either. So can you talk about the data coming up and set the stage for how many cohorts? What is a good? A side effect profile, meaning what amount of rash is okay, looks great versus comparators, and then what is good response?

Yeah, sure. I can talk about sort of how we've framed the program overall, and then Barb, maybe you can talk to kind of how we went through dose escalation. But the most important thing for an ADC is to keep the patients on drug, and that's what we ultimately want to show. So we want to show minimal dose discontinuations, terminations, et cetera. And of course, rash is one of the top contributors. Patients hate rash. It's a chronic sort of building toxicity that certainly can be dose-limiting. And so we want all of this theory to translate in the clinic and show a very low rate of rash and a rate that isn't going to lead to dose discrimination. How much is a low rate of rash? I'd say sub, I don't know, 15%, 20% is how I would pay it.

Speaker 0

That's quite low. We know that Cetux is in the 70% or above range.

Yeah, I was thinking more grade 3 and above, and that would be...

Michael Yee Analyst — UBS

Okay, so I don't have it right in front of me, but if I pull up the Cetuximab label, total rash versus, I agree with you, grade 3 is also a very concerning amount of rash. But what is the total rash and what is grade 3 rash for like cetuximab?

I mean, the total rash rate is quite high.

Speaker 2

I mean, that's like 80%. 70-80%. 70-80%.

Yeah.

Michael Yee Analyst — UBS

Yeah. Right. Okay. So we want to reduce that. Reducing total rash is good too.

What's a good reduction? Like cutting that in half? I think that's a great target. And again, ultimately, we want to be able to show that we're able to keep patients on drug. Okay. And so that's... That's true.

Michael Yee Analyst — UBS

Because we do want the payload to come in too.

Exactly.

Michael Yee Analyst — UBS

Okay. And then in terms of grade three rash, I don't know the number off the top of my head, but what does Cetuximab have for grade three?

I mean, I'd have to look that up too.

Speaker 0

I think it's probably single digits. I mean, it's the grade three rash rate isn't terribly high.

Michael Yee Analyst — UBS

Okay. Yeah, but overall, the rash causes people to drop out.

Speaker 0

Grade three is definitely bad.

Michael Yee Analyst — UBS

If you're saying it's like 9%, low single digits, that's remarkable. I'm not saying you're zero, but you're saying, and why would there be a much rash? Because there shouldn't be this epitope on wild types. So can you explain that?

I mean, I think that's what we saw. What's really encouraging and a good setup for what we're seeing in the clinic is that we did not see rash in the NHP work we did. And we know from the early work that cetuximab and panitumumab did that they saw that in the primate work. And so I think that's a good leading indicator for us that we've effectively really reduced that challenge.

Michael Yee Analyst — UBS

Now, not all human primates are not humans, so, you know, rash is a fairly reasonable model. Mice are definitely worse models for rash, but the bottom line is, given that the data is coming in the next... A few weeks. Significant reductions off the 78% and the 9% is good. The point about it is not because we're coming up with a drug that has less rash. It's to keep patients on drug so that we can see responses, particularly with an antibody drug conjugate, not a monoclonal, because an antibody drug conjugate is going to be more potent on efficacy. Keep them on drug and bring in the payload. So what is a good, how much response rates are we going to get?

I mean, I think it's a great point just on potency, and again, you know, we designed, built this ADC in-house, and we spent a lot of time optimizing the linker payload as well as the epitope to drive both on-target delivery to tumor as well as the bystander effect, and it's those two things that really drive efficacy in an ADC. So when we shared earnings this week, I think we also just upped the expectations on numbers of patients. So we now are guiding towards more like 35 plus patients across this study with 15 or more at the right doses in the right tumor types. So in the past, you know, we've talked about the study design being focused on four tumor types, so head and neck, lung, esophageal, and CRC. You know, I think internally we had identified non-small cell lung and head and neck as being the best opportunities. So once we got into the therapeutic range around four, we really focused on enrolling patients in those two tumor types. So that's going to come through. That was fours in four cohorts?

Michael Yee Analyst — UBS

Four migs per K. Four migs per K, right, which philosophically speaking is plenty of drug. Yes. You also would dose up because many times in cancer, you dose up to a dose limiting toxicity. I mean, the general rule in cancer is give them as much as possible until they can't tolerate it because we want maximal efficacy.

Right.

Michael Yee Analyst — UBS

Would a dose limiting tox be the reason you stop at four or you stop at four because that's plenty of drug?

Yeah. I mean, I think with dose escalation, we're trying to take it up to a point where we'll see DLTs, right? I mean, ultimately, that's what we want to see. What would be a DLT for this drug? Would it be the payload? Or would it be the... It's much more likely to be payload-related. Sorry, I just drank.

Speaker 2

So bottom line is, you're going to four mg per kg. The DLT would be related because of the payload.

Michael Yee Analyst — UBS

That's expected. Good news is it's tolerable. People are not dropping off the drug, and it's plenty of drug to see responses. Right. Now, set the stage then for how much response rate should we get in those expansion cohorts? Because you're at a high dose, we want to see responses.

Yeah, I think so. Here, we enrolled this study 100% in the U.S. So this is top U.S. academic centers. So think MD Anderson, Moffitt, and the like. And then importantly, a very late-line population. So this is on average a fourth line patient population. And so when you think about the therapies available, both in head and neck and lung, it's checkpoints, it's lines of chemo, it's prior EGFR. We took all of those patients.

Speaker 2

When you say fourth line, you're saying that's like the average? The median number of treatments in lung cancer and head and neck is four.

This will be, so three prior lines. Three prior lines. Through our study, they'll be effectively four.

Michael Yee Analyst — UBS

I mean, I know the drugs in head and neck and lung cancer. They are not. Any great options in fourth line? No. Dositaxel, a chemo in second line lung, barely gets you 15% response rates. That's in second line. You're talking fourth line.

Speaker 2

I mean, there's nothing else out there. So appreciate it. They're very heavily pretreated.

Michael Yee Analyst — UBS

I guess I would say that double digit responses rates would be remarkable, but maybe you could set the stage. I'm also not saying that that means the drug doesn't work.

I'm just saying the higher, the better. I think that's right. I think from a benchmark perspective, double digits would be remarkable. I think greater than 30% would be outstanding, and anything above that would be transformational.

Michael Yee Analyst — UBS

I mean, back me off here. I mean, that 30% response rates in fourth line, if I see 30% response rates in fourth line, that is definitely remarkable.

And that's what we're going for. Again, this ADC was designed for potency, and I think we're- Seriously, I've never seen

Speaker 2

30% response rates in fourth line anything.

What's most exciting, too, is where we're ultimately going, of course, is not fourth line. I mean, the next step, the step that we're actively taking is in the second line. So second line head and neck and second line wild type lung. Absolutely. And there's big opportunities for us in both.

Speaker 2

Okay, so we'll look for the response rates.

Michael Yee Analyst — UBS

We'll look for lowered rash. Patients need to stay on. If you have response rates, double digits is great. I'd be shocked if I saw 30%, and that's great. Obviously, we go forward, which sounds promising. Now you want expansion cohort. So you're going to open, what, a big expansion cohort in lung and head and neck?

That would be the goal? Second line lung, I think we'll look at both EGFR experience as well as EGFR naive. That standard of care is changing. As we know, PETO is likely to get approved in frontline, which is an EGFR bispecific. So we're going to want to understand our activity both in patients that have not seen an EGFR and those that had. And we'll have a somewhat of a signal.

Speaker 2

I'm sorry, frame that again.

Michael Yee Analyst — UBS

And obviously, in second-line EGFR, your point is that they're, I mean, I know the first-line agents. You were saying that something else is coming in front of them.

Well, PETO, which is the Maris molecule, now GenMap. Right, for head and neck. Head and neck. They had front-line data that suggests that they'll be moving front-line. Yes, they just reported that data. And so what's really important and is not defined is what happens post-PETO. A lot of the data sets to date have been largely EGFR-naive patients. It's going to be important for us to do both, and one of the things that we think is particularly exciting about our choice of epitope is that it's different, because PETO and all the other bispecifics use cetuximab, whereas we use metuzumab, and we know that some of these patients who progress will mutate off of that binding site.

Michael Yee Analyst — UBS

Now is the... And payload the same, oh, I guess it's not, because this is by specifics. So you're not worried about that. That's a different situation.

And that's what's interesting for us in head and neck. We have the potential not only to bring the unique epitope advantage, but to be the first topo in that field. And I think that is why we need to move quickly and what we're...

Speaker 2

Okay, so in head and neck, you'd want to run EGFR-naive and

Michael Yee Analyst — UBS

EGFR-experienced and see if there's any difference. The point is it could work very well in both because you have a different epitope. So as long as the antibody drags the epitope, then it should bind and therefore drag the payload in. That's all that's needed, as long as there's not like a loss of the epitope. Okay, so in lung cancer, what would be a plan there if the data are good?

I mean, wild-type lung is where there's the most opportunity. In mutant lung, there's other topo ADCs that have advanced. But in wild-type lung, particularly in the squamous setting, there's really nothing available. Datraway, as well as the SAC-TMT data, has been relatively disappointing in squamous lung. And what's so interesting for us with an EGFR is we know in squame that EGFR is very highly expressed, and that's a big unmet need. And so in this data set that we'll be reporting, we're going to have a number of squame and non-squame patients, but that wild-type setting is where we're focused.

Michael Yee Analyst — UBS

I need to fact check myself because I feel that SAC-TMT has had very positive data in combination with chemo in PD-1 negative patients and across PD-1 positive, obviously, with PD-1. But SAC-TMT definitely looks good. I cover Merck. I think it's going to go to first line. There are certainly minimal options in second line. Once again, SAC-TMT is probably going to be docetaxel in second line. They don't care about second line. They're going to go first. But there's definitely room in second line. My question is if it's using the same payload, there's a small chance of mutations that would cause a problem. But the bar is open there, what you're saying in second line.

Yeah, I mean, most of those studies you mentioned are on the mutant side of things, and, you know, we certainly understand the challenge of bringing another topo. So, you know, a topo after topo, I think the jury's still out, at least with our drug. We do have a different epitope, so that could be a way that we could play there. But for us, on the wild-type side, there's much less data, and there's much more open field, including versus SAC-TMT, and so that's where we see a big difference.

Michael Yee Analyst — UBS

And the reason is because, obviously, they were doing that to hit mutant because they didn't want the off-target docs, or what was that?

I think the biology is slightly better in the mutant setting, and I think the DetroA data was also pretty surprising to folks. I think they expected it to work as well in squame as it did in the non-squame payment patients, and they didn't see that. They saw a relatively low ORL.

Michael Yee Analyst — UBS

Yeah, your point is in squames that the other drugs have not done so well. That is certainly true for a data DXD. It did not ultimately get approved, I think, in that setting. And now we're waiting on a Vanzar and some other stuff. But SAC, TMT, I feel maybe better, but this is a different question. Plenty of open room for them. Okay. Anything else to say about that? Otherwise, we look forward to this data in December. I guess, as every company here has said who still has data remaining this year, they say not during Christmas week. I'm not doing that. Some people, like Biogen, say first half of December. I mean, Aruca was just here. They said it's coming very soon.

Not during Christmas. I don't know when our holiday party is. I think it's the 21st or something. It's definitely going to be before that.

Michael Yee Analyst — UBS

Definitely before your holiday party. Okay. Well, I'm hoping for a good holiday party. We are, too. Okay. Let's talk about, in the last 10 minutes, something that is very important, and there's a lot of data here. And so here, let's walk through this because I think it takes some explanation, and once people understand it, it looks pretty interesting. So you have a Vorpicept. It's in metastatic breast cancer, HER2-positive metastatic breast cancer. Can you talk about the ongoing Phase II study, explain that, why it's designed like that, and then we'll talk to your update recently that just happened.

Sure. I mean, Barb can walk through the study design. I think with Evo, what is so compelling about where the program sits right now is we have the opportunity to be the first This is the first and frankly only option for patients that are CD47 high, and that's what's really changed in our story, is an ability to go from being this broad sort of IO approach to a very targeted.

Michael Yee Analyst — UBS

CD47 and perhaps, because in combination, any anti-CD16 antibody that would have.

Any HER2 antibody, but that's exactly how.

Michael Yee Analyst — UBS

My point was that if it was a different, like in colorectal cancer, as long as you had a CD16 antibody, this would go with it.

This is an easy proof of concept. Any FC active antibody, our drug will work in combination with. And so in this case, we're using Herceptin. And that's what we've learned, is that when we see CD47 and we see HER2 expression, our drug is really working phenomenally well. So do you want to touch on the trial design?

Speaker 0

Yeah, so ASPEN9 is the ongoing trial. We had great data in the past. We did a relatively large randomized phase 2 in gastric on the basis of a trastuzumab-based regimen, added a vorpacep, and we saw a good increase in response and durability of outcome. We have a smaller data set in breast cancer with zanidatinib, so now what we want to do is enlarge our experience in breast cancer prior to a phase 3. We are enrolling 120 patients. They will be HER2 positive based on historic archival, and then we want to look very closely at CD47 to understand where the best threshold is. So the cut point that defines CD47 overexpression needs to be optimized before we go into a phase three. So we'll look at our outcome data next year, second half of 2027, and what we're hoping to see is a high response rate in patients who were CD47 overexpressing, a lower response rate in patients who were HER2 negative on fresher biopsy, or CD47 negative. So it's kind of an internal control within the study.

Speaker 2

So let's walk through that. So you plan to enroll 120.

Michael Yee Analyst — UBS

Quote, unquote, HER2 positive second line plus breast cancer patients. If you get 120, the idea is that you will check to see if they have a recent positive HER2 positivity. Is that a fair way? So it's 120 patients because we've got to get them in the study, and the files show that they were HER2 positive at one point, but is that because there's a second biopsy taken, or how do you confirm fresh HER2 positivity?

Speaker 0

Yeah, both. We've really emphasized the importance of sites, investigators getting fresh tissue, but no matter what, we'll take the tissue that they have, and we'll look centrally. And so we're able to confirm HER2 positivity in about... We haven't talked about our data yet, but in general, what you see is somewhere in the range of 60%, 70% of HER2-positive patients can be confirmed on central read.

Michael Yee Analyst — UBS

So let me clarify that. Not because they're getting a fresh biopsy?

Speaker 0

We have encouraged our patients to do so, but a portion of our study population will have had a recent biopsy, and another portion will have had their archival tissue.

Michael Yee Analyst — UBS

And if you use the archival, how do you confirm that they are still HER2 positive?

We also are taking ctDNA. So the ctDNA is blood-based, of course, and that has a relatively high concordance rate in terms of positivity.

Michael Yee Analyst — UBS

So when you roll 120 patients, and I'm going to get to the two cut points, The population first has to be HER2 positivity based on fresh biopsy or based on ctDNA if they did not have a fresh biopsy, and that is basically 90% concordance. Okay, now when we get that, you think how many patients of the 120 will be HER2 positive?

I think it's probably around half, maybe a little bit higher. Again, it's in flux because we're, you know, if you think about when we started enrollment to now, you know, we have a lot of relatives.

Michael Yee Analyst — UBS

Now, you said 60% to 70% historically have HER2 positivity. Then when you take people with fresh biopsy, they're definitely going to be HER2 positive. Otherwise, they wouldn't have gotten into the study. That's fair. Well, some of the patients, well... Are we enrolling patients then taking the first biopsy and they're not HER2 but we let them stay in the study?

Speaker 0

There's the local read would always have to be HER2 positive. There is also the discordance of local versus central confirmation on the same biopsy sample is not always confirmed. Yeah.

But our goal is to make sure that the patients that are in the HER2-positive bucket, if you will, are truly HER2-positive. Because ultimately, that's how our drug works.

Michael Yee Analyst — UBS

Okay, and so without getting into the details of that, once you test either for those, it's about 50% of those are likely to be HER2-positive. Now, when we get to those 60 out of 120, this is the critical part. You are seeking to test this drug, particularly in CD47 high patients, because we want HER2-positivity. Otherwise, obviously, the backbone of her septin is not going to be doing anything to obviously bring ADCC in for the CD47 antibody to work. Makes sense. So what percent of the patients are going to have CD47 high versus low?

It's probably around 50% to 70% depending on how we define the cutoff.

Michael Yee Analyst — UBS

Now, when I recall the gastric data, I recall that there wasn't a huge dramatic difference in response rates. I thought it was like anything above like 5% or something, or could help me out with the numbers, basically have pretty good response rates. So I wouldn't want to cut the cut point too low because we don't want to cut off patients in the market opportunity.

Yeah, I mean, exactly. What we showed in the gastric study, which was our randomized study, is there wasn't a lot of magic in where we set the cut point. I mean, the signal was so strong that you could have just said they have CD47 versus they don't, and that in and of itself would drive a really strong treatment effect. Yeah. So again, you know, if that happens here, now it's still important to define the cutoff because that's going to help inform the commercial opportunity. Okay. But ultimately, you know, when you see that sort of treatment effect, these things get.

Michael Yee Analyst — UBS

I mean, this is a phase two. So let's not get too much into the whereas of, oh, it's post hoc analysis. You looked at those above 5%, but those above 10% really had it, but those above 5%, you know, I don't want to get into that. Just to be clear, the primary endpoint is response rate in HER2-confirmed positivity patients and CD47 high. If I may ask that question, what in the protocol is defined as CD47 high?

We've defined it as sort of on-off, if you will. So CD47 presence versus not.

Michael Yee Analyst — UBS

And presence is what, above 5%?

Yeah, more or less.

Michael Yee Analyst — UBS

And based on the gastric data, above 5%, there was responses. Right, and based off the XANI data as well. Okay, so what percent, it's about 50 to 70 percent. If I get that right, it would be CD47 above 5 percent. So it takes 120, cut it to 60 because those are people who actually are clear to have HER2 positivity, and then 50 percent of the 60 is 30 to get those who have CD47 high. We should have 30 people who have CD47 high, 30 that are CD47 low. Right. And in CD47 Hive, what type of response rate would you expect? And in the low, what is the background? It's very interesting because you almost kind of serve as your own control. Think about that. Exactly. Think about that. Because in the CD47 low, they basically don't have any CD47. So your drug, which obviously blocks as they don't eat meat, is not really going to draw any difference. And that was sort of seen in the gastric data. So it sort of serves as its own self-control because retreating with Herceptin ain't going to do much if you've already failed the HER2. So that should be like, what, 10% response rates?

I mean, that's exactly why we designed the study like this. Yeah, and if you look at what the standard of care post and HER2 in the front line is yet to be defined. So we don't know, but I think when we look at the real-world data, it's abysmal. There was a real-world study out of Asia that was published at the last ESMO, about 600 patients, and they showed 14%, 15% ORR with three or four months PFS. So we know that the bar, so to speak, is low.

Michael Yee Analyst — UBS

Yeah, so it's 15%, again, with a retreatment of a HER2 drug. It's a retreatment on someone who's already failed basically in HER2, and you give them Herceptin. They might have 15% response rates. You're definitely shooting from a lot higher than 15% if you throw in a 4%.

I mean, the other thing interesting about that real-world study is it didn't matter what they got. They could have received a TKI or another round of Herceptin. It was still very low ORR. So if we can double that, I think we have something. And so that's how we're thinking about our...

Michael Yee Analyst — UBS

So that would be 30 patients. If you have 30% response rates, it's like basically double. That's definitely above anything anyone's seen before. And if you double the control arm of 15%, your own self-control, then that would be pretty obvious in a – it is open label, but again, this is like response rates. There's no placebo effect. That's pretty real. All right, and this data will come in the second half of 27. Will you give updates on enrollment? Because just to be clear, you just gave an update on the last week's earning call, and you said we want to go to the full 120. That's what we want to get to. That's the most robust readout.

Yeah, I mean, and I think we feel really good about our enrollment projections, and I think that guidance is right on for us.

Michael Yee Analyst — UBS

And where are you with cash, Jason?

We have cash through mid-28, so we raised $150 million back in January, and we're well-funded to get through all the milestones that we talked about.

Michael Yee Analyst — UBS

Fantastic. Thank you very much, guys.

Thank you so much. Appreciate it.

Analyst Q&A · 1 question
Full-screen source Call document